IRCT20170128032241N2 IRCT 2018-02-16 Alborz Nanomed Tech Co. Effect of oral curcuden on multiple sclerosis patients Evaluation of safety and efficacy of oral curcuden on remitting and relapsing multiple sclerosis patients (RRMS): clinical trial study of Phase A2 2017-10-23 anticipated 68 Complete https://irct.ir/trial/25165 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: Random Numbers Table, Randomization description: Use a random number table, we assign patients the code within the specified interval, then we classify the odd codes in the intervention group and the even codes in the control group, Blinding description: We mark drug with code A and placebo with the code B, only the analyst is aware of this codes, each group of patients receive A or B randomly, the physician and the patient are not aware of this codes. 2 Multiple sclerosis. Intervention 1: Intervention group 1: 34 RRMS patients who received at least 6 months of first line treatment of MS (beta-interferon) but have clinically experienced at least one relapse during medication or an active lesion in their brain or spinal cord. Intervention 2: Control group: 34 RRMS patients who receive at least 6 months of first line treatment of MS (beta-interferon) but have clinically experienc at least one relapse during medication or an active lesion in their brain or spinal cord. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is No more information